CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-2.15%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.76B
AUM Growth
+$2.76B
(+6.6%)
Cap. Flow
+$282M
Cap. Flow
% of AUM
10.19%
Top 10 Holdings %
Top 10 Hldgs %
57.66%
Holding
45
New
8
Increased
20
Reduced
5
Closed
7
Top Buys
| 1 |
Viatris
VTRS
|
$76.2M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$59.6M |
| 3 |
Medtronic
MDT
|
$55.5M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$51.4M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$49.1M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$98.8M |
| 2 |
Merck
MRK
|
$82.1M |
| 3 |
GSK
GSK
|
$65.3M |
| 4 |
Biogen
BIIB
|
$60M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
$49.2M |
Sector Composition
| 1 | Healthcare | 95.18% |
| 2 | Technology | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $250M | 9.05% | 23,000,000 +7,000,000 | +44% | +$76.2M |
|
2
Universal Health Services
UHS
$11.6B
| $232M | 8.39% | 1,600,000 -50,000 | -3% | -$7.25M |
|
3
Sanofi
SNY
$121B
| $205M | 7.43% | 4,000,000 +200,000 | +5% | +$10.3M |
|
4
Zimmer Biomet
ZBH
$21B
| $173M | 6.25% | 1,350,000 +350,000 | +35% | +$44.8M |
|
5
Gilead Sciences
GILD
$140B
| $149M | 5.38% | 2,500,000 +250,000 | +11% | +$14.9M |
|
|
CHNG
6
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $131M | 4.73% | 6,000,000 +2,000,000 | +50% | +$43.6M |
|
|
7
Merck
MRK
$210B
| $123M | 4.45% | 1,500,000 -1,000,000 | -40% | -$82.1M |
|
8
Brookdale Senior Living
BKD
$1.83B
| $113M | 4.08% | 16,000,000 | – | – |
|
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $111M | 4.02% | 3,000,000 +1,610,000 | +116% | +$59.6M |
|
|
WBA
10
DELISTED
Walgreens Boots Alliance
WBA
| $107M | 3.89% | 2,400,000 -1,100,000 | -31% | -$49.2M |
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $107M | 3.89% | 1,375,000 +550,000 | +67% | +$43M |
|
12
Incyte
INCY
$16.5B
| $107M | 3.88% | 1,350,000 +450,000 | +50% | +$35.7M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $100M | 3.63% | 1,300,000 +285,000 | +28% | +$22M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $98.7M | 3.57% | 1,200,000 +625,000 | +109% | +$51.4M |
|
15
Perrigo
PRGO
$3.27B
| $96.1M | 3.48% | 2,500,000 +775,000 | +45% | +$29.8M |
|
16
Myriad Genetics
MYGN
$593M
| $88.2M | 3.19% | 3,500,000 +750,000 | +27% | +$18.9M |
|
17
PTC Therapeutics
PTCT
$3.92B
| $65.3M | 2.36% | 1,750,000 +1,000,000 | +133% | +$37.3M |
|
18
Tenet Healthcare
THC
$16.3B
| $58M | 2.1% | 675,000 -525,000 | -44% | -$45.1M |
|
|
19
Medtronic
MDT
$119B
| $55.5M | 2.01% | +500,000 | New | +$55.5M |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $49.1M | 1.78% | +1,500,000 | New | +$49.1M |
|
21
ZimVie
ZIMV
$532M
| $45.7M | 1.65% | +2,000,000 | New | +$45.7M |
|
|
22
GSK
GSK
$79.9B
| $43.6M | 1.58% | 1,000,000 -1,500,000 | -60% | -$65.3M |
|
23
OraSure Technologies
OSUR
$242M
| $28.8M | 1.04% | 4,250,000 | – | – |
|
|
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
| $28.4M | 1.03% | 500,000 +400,000 | +400% | +$22.7M |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $28.1M | 1.02% | +300,000 | New | +$28.1M |
|